Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ginkgo Bioworks Holdings, Inc.DNA · Entity 5530 | Director | June 11, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ginkgo Bioworks Holdings, Inc.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 25,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 25,000 · Balance 25,000 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2: In accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Program, which became effective on June 11, 2026, the RSUs shall vest on the earlier of June 11, 2027 or the day immediately prior to the date of the next Annual Meeting occurring after the date of grant, in either case, subject to the Reporting Person continuing in service as a Non-Employee Director through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2: In accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Program, which became effective on June 11, 2026, the RSUs shall vest on the earlier of June 11, 2027 or the day immediately prior to the date of the next Annual Meeting occurring after the date of grant, in either case, subject to the Reporting Person continuing in service as a Non-Employee Director through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 15, 2026 21:03 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | GrantRestricted Stock Units · Derivative | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-043293 · wk-form4_1781557411.xml · derivative · entry 1 Kosuri Sri · CIK 0002043887 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Class A Common Stock · 25,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: In accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Program, which became effective on June 11, 2026, the RSUs shall vest on the earlier of June 11, 2027 or the day immediately prior to the date of the next Annual Meeting occurring after the date of grant, in either case, subject to the Reporting Person continuing in service as a Non-Employee Director through such vesting date. F2 · derivative.expiration_date: In accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Program, which became effective on June 11, 2026, the RSUs shall vest on the earlier of June 11, 2027 or the day immediately prior to the date of the next Annual Meeting occurring after the date of grant, in either case, subject to the Reporting Person continuing in service as a Non-Employee Director through such vesting date. Read SEC document |
| June 12, 2025 Filed Jun 13, 2025 20:13 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | GrantStock Option · Derivative | 34,375 | $0.00 Strike: $9.29 | $0.00 |
DisclosureSEC source: 0001127602-25-017481 · form4.xml · derivative · entry 3 Kosuri Sri · CIK 0002043887 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,375 Underlying: Class A Common Stock · 34,375 shares Expires 2035-06-12 F3 · derivative.exercise_date: In accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Program, which became effective on June 12, 2025, the option shall vest and become exercisable in substantially equal installments on each of the first three anniversaries of the date of grant, such that the option shall be fully vested on the third anniversary of the date of grant, subject to the Non-Employee Director continuing in service as a Non-Employee Director through each such vesting date. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:13 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionRestricted Stock Units · Derivative | 24,067 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001127602-25-017481 · form4.xml · derivative · entry 2 Kosuri Sri · CIK 0002043887 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 24,067 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F1 · kind: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: In accordance with the Issuer's Non-Employee Director Compensation Program, the RSUs granted on November 6, 2024 vested in full in Class A shares on June 11, 2025, which was the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, and was subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date. F2 · derivative.expiration_date: In accordance with the Issuer's Non-Employee Director Compensation Program, the RSUs granted on November 6, 2024 vested in full in Class A shares on June 11, 2025, which was the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, and was subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:13 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 24,067 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-017481 · form4.xml · nonDerivative · entry 1 Kosuri Sri · CIK 0002043887 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,067 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 22:18 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | GrantRestricted Stock Units · Derivative | 24,067 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-026859 · form4.xml · derivative · entry 3 Kosuri Sri · CIK 0002043887 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,067 Underlying: Class A Common Stock · 24,067 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F5 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: The vesting date of the RSUs and additional initial options, and in the case of the additional initial options, the exercise date, will be the day immediately prior to the date of the next Annual Meeting of Shareholders of the Issuer occurring after the date of grant, in either case, subject to the Reporting Person continuing in service as a Non-Employee Director through such date. F4 · derivative.expiration_date: The vesting date of the RSUs and additional initial options, and in the case of the additional initial options, the exercise date, will be the day immediately prior to the date of the next Annual Meeting of Shareholders of the Issuer occurring after the date of grant, in either case, subject to the Reporting Person continuing in service as a Non-Employee Director through such date. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 22:18 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | GrantStock Option · Derivative | 30,911 | $0.00 Strike: $8.31 | $0.00 |
DisclosureSEC source: 0001127602-24-026859 · form4.xml · derivative · entry 2 Kosuri Sri · CIK 0002043887 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,911 Underlying: Class A Common Stock · 30,911 shares Expires 2034-11-06 F3 · shares: In accordance with the Non-Employee Director Compensation Program of the Issuer, the Black-Scholes value of the additional initial option award as of the grant date is $200,000. F4 · derivative.exercise_date: The vesting date of the RSUs and additional initial options, and in the case of the additional initial options, the exercise date, will be the day immediately prior to the date of the next Annual Meeting of Shareholders of the Issuer occurring after the date of grant, in either case, subject to the Reporting Person continuing in service as a Non-Employee Director through such date. F3 · derivative.underlying_shares: In accordance with the Non-Employee Director Compensation Program of the Issuer, the Black-Scholes value of the additional initial option award as of the grant date is $200,000. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 22:18 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | GrantStock Option · Derivative | 60,240 | $0.00 Strike: $8.31 | $0.00 |
DisclosureSEC source: 0001127602-24-026859 · form4.xml · derivative · entry 1 Kosuri Sri · CIK 0002043887 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,240 Underlying: Class A Common Stock · 60,240 shares Expires 2034-11-06 F1 · shares: In accordance with the Non-Employee Director Compensation Program of the Issuer, the Black-Scholes value of the initial option award as of the grant date is $400,000. F2 · derivative.exercise_date: The initial stock options shall vest and become exercisable in substantially equal installments on each of the first three anniversaries of the date of grant, such that the initial stock options shall be fully vested on the third anniversary of the date of grant, subject to the Reporting Person continuing in service as a Non-Employee Director through such date. F1 · derivative.underlying_shares: In accordance with the Non-Employee Director Compensation Program of the Issuer, the Black-Scholes value of the initial option award as of the grant date is $400,000. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.